Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

     

News

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders

🕔11/14/2018 10:20:11 AM 1282

Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Chairman Address to Shareholders.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chief Executive Officer Appointment

🕔11/14/2018 8:23:04 AM 1258

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has appointed Mr Steven Lydeamore as Chief Executive Officer, effective as of 3rd December 2018.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔10/31/2018 10:01:44 AM 1004

Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th September 2018. The Company's cash position at the end of the quarter stood at $7.1m.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) APVMA Approval for Detach

🕔10/29/2018 9:16:27 AM 1213

Anatara Lifesciences (ASX:ANR) is pleased to announce that the Australian Pesticides and Veterinary Medicines Authority has registered Detach(R) with the approved label, "To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets".

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Formation of Product Development Advisory Board

🕔10/23/2018 2:39:28 PM 1518

Anatara Lifesciences (ASX:ANR), a company focused on commercialising innovative products for gut health, is pleased to announce the formation of its Product Development Advisory Board. The Advisory Board consists of five key external experts: Dr Rebecca Burgell, Dr Jakob Begun, Prof Barry Campbell, Assoc Prof Simon Keely and Prof Peter Gibson, who will serve as the Chairman.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) 2018 Annual Report

🕔10/9/2018 8:31:26 AM 1614

Anatara Lifesciences (ASX:ANR) is pleased to release its Annual Report, for the year ended 30th June 2018.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) CEO, Dr Mel Bridges Announces Retirement

🕔5/17/2018 8:30:21 AM 3237

Anatara Lifesciences Ltd (ASX:ANR) announces that Executive Chairman, Dr Mel Bridges has informed the Board of his wish to retire from his role at Anatara with immediate effect and the Board has formally accepted his resignation.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation on Zoetis Exclusive Global License

🕔5/16/2018 1:39:11 PM 2694

Anatara Lifesciences (ASX:ANR) is pleased to release a new investor presentation following the announcement that Anatara had established an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Exclusive Global License Agreement with Zoetis

🕔5/15/2018 9:50:29 AM 2993

Anatara Lifesciences (ASX:ANR) is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R) as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔4/19/2018 8:27:06 AM 3208

Anatara Lifesciences (ASX:ANR) today released its Appendix 4C financial report for the quarter ending 31st March 2018.

Read Full Article
###

28,742 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 60) (Last 30 Days: 486) (Since Published: 28742) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Quarterly Report

Social Media